GenSci and RTW Investments Announce Strategic Partnership on Anti-TSHR Antibody GS-098 (YB-101) for Graves’ Disease and Thyroid Eye Disease, With Global Ex-China Development Being Led by Yarrow Bioscience
Shanghai Scizeng Medical Technology Co., LTD, a subsidiary of Changchun GeneScience Pharmaceutical Co., Ltd. (“GenSci”), RTW Investments, LP (“RTW”), and Yarrow Bioscience, Inc. (“Yarrow”) today announced an exclusive global ex-China license agreement for GS-098, a clinical-stage, first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves’ disease (GD) and thyroid eye disease (TED). Founded in 1997, GenSci – a subsidiary of Changchun High‑Tech Industries Co., Ltd (“Changchun High-Tech”) – is a fully integrated, leading biopharmaceutical company based in China with a broad innovative pipeline across endocrinology, immune & pulmonary, oncology, and women’s health as well as commercial leadership in recombinant human growth hormone (rhGH) products. Yarrow was founded to develop transformative therapies for autoimmune thyroid diseases and backed by RTW, a preeminent global, full life-cycle life sciences investment firm based in New York.
